Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix

[1]  Gang Chen,et al.  Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix , 2013, BMC Cancer.

[2]  T. Todenhöfer,et al.  Thymidine kinase and cancer monitoring. , 2012, Cancer Letters.

[3]  A. Stenzl,et al.  Exposed proliferation antigen 210 (XPA‐210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications , 2012, BJU international.

[4]  J. Cuzick,et al.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. , 2012, The Lancet. Oncology.

[5]  A. Stenzl,et al.  XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence , 2012, World Journal of Urology.

[6]  S. Eriksson,et al.  High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma , 2012, Tumor Biology.

[7]  Anika O. Joseph,et al.  Automated Detection of Dual p16/Ki67 Nuclear Immunoreactivity in Liquid-Based Pap Tests for Improved Cervical Cancer Risk Stratification , 2012, Annals of Biomedical Engineering.

[8]  F. Cheung,et al.  A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong: 1997-2006. , 2011, Hong Kong medical journal = Xianggang yi xue za zhi.

[9]  Ma Heng-hui.  Significance of TK1 and Ki-67 expression in ovarian serous adenocarcinoma , 2011 .

[10]  A. Stenzl,et al.  XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma , 2011, World Journal of Urology.

[11]  Yen-Ling Chen,et al.  Regulation and Functional Contribution of Thymidine Kinase 1 in Repair of DNA Damage* , 2010, The Journal of Biological Chemistry.

[12]  Y. Li,et al.  Thymidine Kinase 1 is a Potential Marker for Prognosis and Monitoring the Response to Treatment of Patients with Breast, Lung, and Esophageal Cancer and Non-Hodgkin's Lymphoma , 2010, Nucleosides, nucleotides & nucleic acids.

[13]  F. Gasparri,et al.  Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays. , 2009, European journal of cell biology.

[14]  Staffan Eriksson,et al.  Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management. , 2009, Molecular medicine reports.

[15]  A. Bankfalvi,et al.  A 7.5-year prospective study of longer than 18 months type-specific human papillomavirus persistence in a routine cytology-based cervical screening population of about 31 000 women in West Germany , 2009, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[16]  Young Tae Kim,et al.  Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. , 2008, Journal of gynecologic oncology.

[17]  Ondrej Topolcan,et al.  The role of thymidine kinase in cancer diseases. , 2008, Expert opinion on medical diagnostics.

[18]  Y. Min.  Expression of TK1 and Ki-67 in prostate diseases , 2008 .

[19]  V. Alves,et al.  Comparative study of the expression of cellular cycle proteins in cervical intraepithelial lesions. , 2006, Pathology, research and practice.

[20]  R. Silvestrini.  Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk Model , 2005, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[21]  S. Robboy,et al.  Ki67 Predicts Progression in Early CIN: Validation of a Multivariate Progression-Risk Model , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[22]  J. Underwood.  General and Systematic Pathology , 2004 .

[23]  H. Ngan,et al.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[24]  S. Eriksson,et al.  Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. , 1996, European journal of cell biology.

[25]  Kathleen R. Cho,et al.  Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. , 1996, Cancer research.

[26]  L. G. Koss,et al.  Cervical Cancer , 1981, Current Topics in Pathology.